Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $1.77 Million - $2.32 Million
75,000 Added 33.33%
300,000 $7.93 Million
Q4 2021

Feb 18, 2022

BUY
$20.0 - $32.29 $4.5 Million - $7.27 Million
225,000 New
225,000 $7.16 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Tcg Crossover Management, LLC Portfolio

Follow Tcg Crossover Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcg Crossover Management, LLC with notifications on news.